Protocol Ledger

NCT05918211 · Phase III · RECRUITING

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Interventional Phase III clinical trial protocol NCT05918211 sponsored by Mezzion Pharma Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-30 Enrollment: 436 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05918211
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)436 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05918211
Protocol FieldVerified Registry Value
NCT IdentifierNCT05918211
Consolidated Lead SponsorMezzion Pharma Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment436 participants (ESTIMATED)
Registered Start Date2023-10-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI